Bhoola, K. D., C. D. Figueroa and K. Worthy. 1992. Bioregulation of kinins - kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1-80.
Brian, J. and R. Rosario. 2005. Hypertension: a review and rationale of treatment. Disease-a-Month 51:548-614.
Chen, S. C., J. Z. Su, K. Wu, W. Y. Hu, D. G. Gardner and D. G. Chen. 1998. Early captopril treatment prevents hypertrophy dependent gene expression in hearts of SHR. Am. J. Physiol. 274:1511-1517.
Cheng, F. Y., Y. T. Liu, T. C. Wan, K. M. Lai and L. C. Lin. 2007a. The study on development of bioactive peptides derived from chicken bone protein I: preparation of chicken leg bone hydrolysates and ACE inhibitory activity. Taiwan J. Agric. Chem. Food Sci. 45:21-26.
Cheng, F. Y., Y. T. Liu, T. C. Wan, C. M. Chen and L. C. Lin. 2007b. The study on development of bioactive peptides derived from chicken bone protein II: antioxidative activity. Taiwan J. Agric. Chem. Food Sci. 45:84-90.
Cheng, F. Y., Y. T. Liu, T. C. Wan, L. C. Lin and R. Sakata. 2008. The development of angiotensin I converting enzyme inhibitor derived from chicken bone protein. Anim. Sci. J. 79:121-127.
Cohen, M. L. 1985. Synthetic and fermentation-derived angiotensin converting enzyme inhibitors. Annu. Rev. Pharmacol. Toxicol. 25:307-323.
Dhlof, B., K. Pennert and L. Hansson. 1992. Reversal of left ventricular hypertrophy in hypertensive patients. Am. J. Hypertens. 5:95-110.
Diez, J. and C. Laviades. 1997. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc. Res. 35: 202-205.
Freslon, J. L. and J. F. Giudicelli. 1983. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br. J. Pharmacol. 80:533-543.
Habib, G. 1997. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin. Ther. 19:39-52.
Hu, W. Y., Y. J. Han, L. Z. Gu, M. Piano and P. de Lanerolle. 2007. Involvement of ras-regulated myosin light chain phosphorylation in the captopril effects in spontaneously hypertensive rats. Am. J. Hyperten. 20:53-61.
Ikeda, Y., T. Nakamura, H. Takano, H. Kimura, J. E. Obata, S. Takeda, A. Hata, K. Shido, S. Mochizuki and Y. Yoshida. 2000. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. J. Lab. Clin. Med. 135:353-359.
Ishimitsu, T., T. Honda, S. Ohta, A. Akashiba, T. Takahashi, T. Kameda, M. Yoshii, J. Minami, M. Takahashi, H. Ono and H. Matsuoka. 2006. Cardiorenal protective effects of yearlong antihypertensive therapy with a angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rat. Am. J. Hyperten. 19:1233-1240.
Miguel, M., I. Recio, J. A. Gomez-Ruiz, M. Ramos and R. Lopez-Fandino. 2004. Angiotensin I-converting enzyme inhibitory activity of peptides derived from egg white proteins by enzymatic hydrolysis. J. Food Prot. 67:1914-1920.
Moalic, J. M., J. Bercovici and B. Swynghedauw. 1984. Moysin heavy chain and actin fractional rates of synthesis in normal and overload rat heart ventricles. J. Mol. Cell Cardiol. 16:875-884.
Jang, A. and M. Lee. 2005. Purification and identification of angiotensin converting enzyme inhibitory peptides from beef hydrolysates. Meat Sci. 69:653-661.
Johnston, C. I., L. M. Burrell, R. Perich, K. Jandeleit and B. Jackson. 1992. The tissue renin-angiotensin system and its functional role. Clin. Exp. Pharmacol. Physiol. 19:1-5.
Muguruma, M., K. Katayama, H. Fuchu and M. Sugiyama. 2003. Peptic hydrolysate of porcine crude myosin has many active fractions inhibiting angiotensin I-converting enzyme. Asian-Aust. J. Anim. Sci. 16:1384-1389.
Jung, W. K., E. Mendis, J. Y. Je, P. J. Park, B. W. Son, H. C. Kim, Y. K. Choi and S. K. Kim. 2006. Angiotensin I-converting enzyme inhibitory peptide from yellowfin sole (Limanda aspera) frame protein and its antihypertensive effect in spontaneously hypertensive rats. Food Chem. 94:26-32.
Ondetti, M. A., B. Rubin and D. W. Cushman. 1977. Design of specific inhibition of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Sci. 196:441-444.
Ondetti, M. A., N. J. Williams, E. F. Sabo, J. Pluvec, E. R. Weaver and O. Kocy. 1971. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca: isolation, elucidation of structure and synthesis. Biochem. 10:4033-4042.
Kannel, W. B. 1996. Blood pressure as a cardiovascular risk factor. J. Am. Med. Assoc. 275:1571-1576.
Katayama, K., H. Fuchu, A. Sakata, S. Kawahara, K. Yamauchi, Y. Kawamura and M. Muguruma. 2003. Angiotensin I-converting enzyme inhibitory activities of porcine skeletal muscle proteins following enzyme digestion. Asian-Aust. J. Anim. Sci. 16:417-424.
Perski, A., A. Hamsten, K. Lindvall and T. Theorell. 1988. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am. Heart J. 116:1369-1373.
Saiga, A., T. Okumura, T. Makihara, S. Katsuta, T. Shimizu, R. Yamada and T. Nishimura. 2003. Angiotensin I-Converting enzyme inhibitory peptides in a hydrolyzed chicken breast muscle extract. J. Agric. Food Chem. 51:1741-1745.
Laragh, J. H., L. Bear, H. R. Brunner, F. G. Buhler, J. E. Ealey and E. D. Vaughan. 1972. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am. J. Med. 52:633-652.
Sipola, M., P. Finckenberg, J. Santisteban, R. Korpela, H. Vapaatalo and M. L. Nurminen. 2001. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J. Physiol. Pharmacol. 52: 745-754.
Li, G., G. Le, Y. Shi and S. Shrestha. 2004. Angiotensin I-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutr. Res. 24:469-486.
Tsutsui, H., Y. Ishibashi, M. Takahashi, T. Namba, H. Tagawa, K. I. Yoshida and A. Takeshita. 1999. Chronic colchicine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. J. Mol. Cell Cardiol. 31:1203-1213.
Lee, K. J., S. B. Kim, J. S. Ryu, H. S. Shin and J. W. Lim. 2005. Separation and purification of angiotensin converting enzyme inhibitory peptides derived from goat`s milk casein hydrolysates. Asian-Aust. J. Anim. Sci. 18:741-746.
Turner, A. J. and N. M. Hooper. 2002. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol. Sci. 23:177-183.
Materson, B. J., D. J. Reda and D. W. Williams. 1998. Comparison of effects of antihypertensive drugs on heart rate: changes from baseline by baseline group and over time. Am. J. Hypertens. 11:597-601.
Vercruysse, L., J. V. Camp and G. Smagghe. 2005. ACE inhibitory peptides derived from enzymatic hydrolysates of animal muscle protein: A review. J. Agric. Food Chem. 53:8106-8115.
Materson, B. J., D. J. Reda and D. W. Williams. 1999. Effects of antihypertensive single-drug therapy on heart rate. Am. J. Hypertens. 12: 9-11.
Wu, J. and X. Ding. 2001. Hypotensive and physiological effect of angiotensin converting enzyme inhibitory peptides derived from soy protein on spontaneously hypertensive rats. J. Agric. Food Chem. 49:501-506.
Miguel, M., R. Lopez-Fandino, M. Ramos and A. Aleixandre. 2005. Short-term effect of egg white hydrolysate products on arterial blood pressure of hypertensive rats. Br. J. Nutr. 94: 731-737.
Miguel, M., R. Lopez-Fandino, M. Ramos and A. Aleixandre. 2006. Long-term intake of egg white hydrolysate attenuates the development of hypertension in spontaneously hypertensive rats. Life Sci. 78:2960-2966.
Yang, H. Y., S. C. Yang, J. R. Chen, Y. H. Tzeng and B. C. Han. 2004. Soybean protein hydrolysate prevents the development of hypertension in spontaneously hypertensive rats. Br. J. Nutr. 92:507-512.